229 related articles for article (PubMed ID: 36224755)
1. Identification and Validation of Novel Biomarkers and Potential Targeted Drugs in Cholangiocarcinoma: Bioinformatics, Virtual Screening, and Biological Evaluation.
Wang J; Zhu W; Tu J; Zheng Y
J Microbiol Biotechnol; 2022 Oct; 32(10):1262-1274. PubMed ID: 36224755
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma.
Qin X; Song Y
Med Sci Monit; 2020 May; 26():e921815. PubMed ID: 32435051
[TBL] [Abstract][Full Text] [Related]
3. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma.
Li H; Long J; Xie F; Kang K; Shi Y; Xu W; Wu X; Lin J; Xu H; Du S; Xu Y; Zhao H; Zheng Y; Gu J
Oncol Rep; 2019 Nov; 42(5):1833-1842. PubMed ID: 31545466
[TBL] [Abstract][Full Text] [Related]
5. Identification of a prognosis-related ceRNA network in cholangiocarcinoma and potentially therapeutic molecules using a bioinformatic approach and molecular docking.
Gao X; Zhang W; Jia Y; Xu H; Zhu Y; Pei X
Sci Rep; 2022 Sep; 12(1):16247. PubMed ID: 36171401
[TBL] [Abstract][Full Text] [Related]
6. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
7. Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression data.
Zhong W; Dai L; Liu J; Zhou S
Mol Med Rep; 2018 Apr; 17(4):5744-5753. PubMed ID: 29436659
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide identification of a competing endogenous RNA network in cholangiocarcinoma.
Li G; Liu T; Zhang B; Chen W; Ding Z
J Cell Biochem; 2019 Nov; 120(11):18995-19003. PubMed ID: 31270845
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma.
Lin P; Zhong XZ; Wang XD; Li JJ; Zhao RQ; He Y; Jiang YQ; Huang XW; Chen G; He Y; Yang H
Oncol Rep; 2018 Dec; 40(6):3189-3198. PubMed ID: 30272356
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses.
Wu HY; Xia S; Liu AG; Wei MD; Chen ZB; Li YX; He Y; Liao MJ; Hu QP; Pan SL
Mol Med Rep; 2019 Dec; 20(6):5002-5020. PubMed ID: 31638221
[TBL] [Abstract][Full Text] [Related]
11. CHST4 might promote the malignancy of cholangiocarcinoma.
Zhang G; Liu X; Jian A; Zheng K; Wang H; Hao J; Zhi S; Zhang X
PLoS One; 2022; 17(3):e0265069. PubMed ID: 35294478
[TBL] [Abstract][Full Text] [Related]
12. Identification of hub genes and pathways in cholangiocarcinoma by coexpression analysis.
Kong J; Shen S; Zhang Z; Wang W
Cancer Biomark; 2020; 27(4):505-517. PubMed ID: 32116234
[TBL] [Abstract][Full Text] [Related]
13. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.
Ke K; Lin J; Huang N; Yan L; Liao R; Yang W
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1888. PubMed ID: 37688511
[TBL] [Abstract][Full Text] [Related]
15. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data.
Cao J; Sun L; Li J; Zhou C; Cheng L; Chen K; Yan B; Qian W; Ma Q; Duan W
Oncol Rep; 2018 Sep; 40(3):1422-1434. PubMed ID: 29956786
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
17. Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.
Wu G; Wang Q; Wang D; Xiong F; Liu W; Chen J; Wang B; Huang W; Wang X; Chen Y
Clin Transl Med; 2023 Dec; 13(12):e1502. PubMed ID: 38050190
[TBL] [Abstract][Full Text] [Related]
18. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
19. Expressional and prognostic value of HPCAL1 in cholangiocarcinoma via integrated bioinformatics analyses and experiments.
Ma M; Zeng G; Li J; Liang J; Huang L; Chen J; Lai J
Cancer Med; 2023 Jan; 12(1):824-836. PubMed ID: 35645147
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA CDR1as Exerts Oncogenic Properties Partially through Regulating MicroRNA 641 in Cholangiocarcinoma.
Li D; Tang Z; Gao Z; Shen P; Liu Z; Dang X
Mol Cell Biol; 2020 Jul; 40(15):. PubMed ID: 32423991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
